No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
814
ZymoGenetics Acquisition Highlights Competitive Hepatitis C Treatment Race
Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
FDA Hopes to Keep Pharma Honest With “Bad Ad” Program
Last week, the FDA unveiled its “Bad Ad” program to encourage physicians to report questionable pharmaceutical sales pitches.
Burrill Report: Biotech Innovation Gets the Cash
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.